Home  »  Finance   »  Is Novo Nordisk A/S (NYSE: NVO) A Great Stock To I...

Is Novo Nordisk A/S (NYSE: NVO) A Great Stock To Invest In?

Novo Nordisk A/S (NYSE:NVO) traded at $138.56 at last check on Tuesday, 01/24/23, made a downward move of -0.96% on its previous day’s price.

Looking at the stock we see that its previous close was $139.90 and the beta (5Y monthly) reads 0.35 with the day’s price range being $139.12 – $144.78. The company has a trailing 12-month PE ratio of 41.56. In terms of its 52-week price range, NVO has a high of $144.78 and a low of $92.69. The company’s stock has gained about 5.59% over that past 30 days.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Novo Nordisk A/S has a market cap of $240.18 billion. With its Forward Dividend at 1.60 and a yield of 1.14%, the company’s investors could be anxious for the NVO stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.85, with the EPS growth for the year raised at $3.48 for 2022 and $4.29 for next year. These figures represent 22.50% and 23.30% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $6.71 billion, with a low of $6.56 billion and a high of $6.82 billion. The median projection represents growth squeezing down to 27.80% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $25.09 billion, or 30.10% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the NVO stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 27 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 7 have rated the Novo Nordisk A/S (NVO) stock as a Hold, while 14 rate it as a Buy. 2 analyst(s) rate it as overweight while 1 of them rated it as underweight, whereas 3 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the NVO stock currently stands at 14.90, and the most recent price level today is 1.33% off its SMA20 and 7.52% from its 50-day simple moving average. The RSI (14) is pointing at 60.38 while the volatility over the past week is 1.60% and jumps to 1.45% over the past one month. The beta value is 0.50, while the average true range (ATR) is currently pointing at 2.53. The average price target for the stock over the next 12 months is $138.72, with the estimates having a low of $75.50 and a high of $174.72. These price ends are 45.51% and -26.1% off the today’s price level respectively, although investors could be excited at the prospect of a -6.65% if the NVO share price touches on the median price of $147.78.

Let’s briefly compare Novo Nordisk A/S (NVO) stock to its peers. We find that today’s price change of -0.96% and 46.71% over the past 12 months for NVO competes that of Eli Lilly and Company (LLY), which has seen its stock price rise 0.40% in the latest trading session and is 42.51% over the last one year. Another of its peers Sanofi (SNY) has gained 0.87% today, and was -4.78% down over the past year, while Bristol-Myers Squibb Company (BMY) is also up 0.26% yet, while its price remains in the green at 13.85% over the same period. Novo Nordisk A/S has a P/E ratio of 41.56 compared to Eli Lilly and Company’s 52.06 and Sanofi’s 17.62. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -1.45% and -1.08%, respectively, in early deals.

Coming back to Novo Nordisk A/S (NYSE:NVO), we note that the average 3-month trading volume was 1.42 million, while that of the preceding 10-day period stands at 1.6 million. Current shares outstanding are 2.26 billion.

The insiders hold 26.40% of the company’s shares while institutions hold 8.40%. The data shows that short shares as of Dec 29, 2022, stood at 1.84 million at a short ratio of 1.38. This represents a 0.08% short interest in shares outstanding on Dec 29, 2022. Shares short fall in December from the previous month at 2.08 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock 3.37% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.

 

We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam